The product is currently being evaluated in head and neck cancer patients to prevent relapse and extend remission periods following surgery and adjuvant therapy. TG4050 is designed to stimulate and prime the patient's immune system against cancer by targeting tumor-specific genetic mutations (neoantigens).

The licensing deal secures Transgene's access to NEC's AI-driven neoantigen prediction platform for the continued development of TG4050. It also grants the French company the necessary rights for the further clinical development, commercialization, and potential sub-licensing of the drug candidate. For its part, NEC will retain full ownership and operational control of its AI platform and will support Transgene in conducting subsequent clinical activities.

On the financial front, NEC will receive a technology access fee of 2.5 million euros in Transgene shares, plus an additional 2.5 million euros in cash to be paid in installments through early 2028. A further milestone-based payment is planned, partially payable in Transgene shares. Finally, NEC is eligible for additional development-related payments, the amounts of which remain confidential, as well as double-digit royalties on profits or licensing revenue.

Oddo BHF believes that "the agreement limits the immediate impact on cash flow while aligning the interests of both partners toward the clinical and commercial success of TG4050."

Analysts added that they view the deal as strategically positive for Transgene, as it strengthens control over the drug candidate in a high-potential indication at a pivotal stage of development. The "Outperform" rating on Transgene stock is maintained, with a price target confirmed at 1.10 euros.